Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Abstract EN

Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors.

The toxicity profile of such agents is characterized by a typical pattern of cutaneous reactions.

In this paper we reviewed the current available data regarding the clinical significance of skin reaction due to EGFR targeted agents.

We show that skin toxicity can be considered as predictive marker of response to such drugs and that it is not disease specific; however its potential prognostic value is still to be proven.